Wire · opportunities
FDA approves pancreatic cancer drug Sasse credits with extending his life
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 August 2026 · Fusion42 review
The FDA approved Rasonque, a new pancreatic cancer drug by Revolution Medicines that nearly doubles median survival time compared to standard chemotherapy, and has been credited by former UF President Ben Sasse with extending his life. The drug offers an expedited treatment option for metastatic pancreatic cancer and costs $39,800 for a 30-day supply with possible co-pay assistance for insured patients.
This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 16 Oct 2026.
◆ ◆ The Wire takeaway
Cancer drug approvals that significantly extend life create new standards for pancreatic cancer care and open quick market access. You should prepare to navigate faster regulatory timelines and competitive pressure from Revolution Medicines in oncology treatments.
◆ Coverage
48 sources · first reported 26 Aug 2026 · latest 16 Oct 2026
◆ Related on Wire
◆ Topics